$22.740
0.000 (0.00%)收盘时
FMS 资讯
FMS 事件
Fresenius Medical Care Launches €1B Share Buyback Program
Fresenius Medical Care announced the launch of the first tranche of its new share buyback program with a total volume of around EUR 1B. The first tranche, amounting up to EUR 600M, was initiated May 28 and is expected to be completed by December 15, 2026.
Fresenius Medical Care Plans €1B Share Buyback
Fresenius Medical Care intends to execute a new share buyback program with a total volume of around EUR 1B. The program shall be executed in tranches over a period of 12 months from its start. It is expected to begin in the near future and only a few weeks after the previous share buyback program was successfully completed on April 30.
Fresenius Medical Care Reappoints CFO Martin Fischer Until 2031
The Supervisory Board of Fresenius Medical Care has reappointed CFO and Management Board Member Martin Fischer for a period of five years until 2031.
Fresenius Medical Care Expects Flat Revenue Growth in 2026
In 2026, Fresenius Medical Care expects revenue growth to be broadly flat compared to prior year. The company expects operating income to remain on a consistent level, with a range between a positive and negative mid-single digit percent growth rate compared to prior year. The expected growth rates for 2026 are at constant currency and excluding special items in operating income. The 2025 basis for the revenue outlook is EUR19.628B and for the operating income outlook is EUR2.212B.
Fresenius Medical Care Reports Q1 Revenue of EUR 4.612B
Reports Q1 revenue EUR4.612B vs. EUR4.881B last year. "Fresenius Medical Care delivered continued operational and financial progress in the Q1, with organic revenue growth, improved profitability and adjusted EPS growth. Operating income growth was in line with our planned phasing," said Helen Giza, CEO of Fresenius Medical Care. "Care Delivery posted strong operating income growth supported by positive TDAPA effects. Excluding positive TDAPA effects, underlying Care Delivery operating income improved by 6%. We are pleased with the speed of the rollout of our innovative 5008X CAREsystem, now available in around 100 clinics and with more than 100,000 treatments performed." Giza continued, "Through focused execution of our FME Reignite strategy, we remain on track to maintain Group operating income at a consistent high level while overcoming significant regulatory headwinds. We confirm our outlook for 2026 and are firmly committed to creating long-term value for our shareholders."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。